Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049984 · ClinicalTrials.gov registry record · Phase 4
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
A Phase 4 study of Parkinson's Disease, sponsored by Teva Neuroscience.
- Completed
- Registry status
- Phase 4
- Development phase
- 328
- Enrollment target
- 20
- Study locations
NCT01049984: Completed Phase 4 study of Parkinson's Disease, sponsored by Teva Neuroscience.
NCT01049984 is a Phase 4 study of Parkinson's Disease that has completed, run by Teva Neuroscience. The registered enrollment target is 328 participants, below the 633-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01049984, a Phase 4 study of Parkinson's Disease, has completed, sponsored by Teva Neuroscience.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 328 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
Primary Outcome
The UPDRS was developed as a comprehensive tool to monitor the impact of Parkinson's Disease and the degree of disability caused. Version 3 of UPDRS contains four parts, three of which are totaled and reported in this outcome. Part I is a clinician's evaluation of mentation (mental activity or state of mind), cognition (ability to acquire knowledge), behaviour and mood. Part II is the participants' evaluation of the disease's impact on normal activities. Part III is a clinician's evaluation of m
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rasagiline
Study Locations (20)
California
- Teva Investigational Site 15 - Fountain Valley
- Teva Investigational Site 19 - Fresno
- Teva Investigational Site 36 - Fresno
- Teva Investigational Site 04 - La Jolla
- Teva Investigational Site 29 - Reseda
- Teva Investigational Site 69 - San Francisco
- Teva Investigational Site 02 - Sunnyvale
- Teva Investigational Site 43 - Ventura
Florida
- Teva Investigative Site 63 - Atlantis
- Teva Investigational Site 30 - Boca Raton
- Teva Investigational Site 13 - Clearwater
- Teva Investigational Site 70 - Sunrise
- Teva Investigational Site 41 - Tampa
- Teva Investigational Site 61 - Vero Beach
Arizona
- Teva Investigational Site 34 - Phoenix
- Teva Investigational Site 42 - Sun City
Connecticut
- Teva Investigational Site 44 - Fairfield
- Teva Investigational Site 07 - Manchester
Delaware
- Teva Investigational Site 25 - Newark
Georgia
- Teva Investigational Site 01 - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
What the finished NCT01049984 record still lists
NCT01049984 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, below the 633-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01049984 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01049984 about?
NCT01049984 is a clinical study titled "Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease". To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
What is the current status of trial NCT01049984?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 328 participants. The study started on 2009-12. Estimated completion is 2012-10.
What conditions does trial NCT01049984 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01049984?
The interventions under investigation include: Placebo (DRUG), Rasagiline (DRUG).
Who is sponsoring clinical trial NCT01049984?
This trial is sponsored by Teva Neuroscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049984 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01049984's enrollment target sits among peer trials
328 23rd of 158 higher than 136 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
COMPLETED · Phase 4
-
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
COMPLETED · Phase 4
-
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia